ImmuPharma plc (LON:IMM) traded down 7.3% on Friday. The stock traded as low as GBX 1.07 ($0.01) and last traded at GBX 1.15 ($0.01). 269,778 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 1,793,761 shares. The stock had previously closed at GBX 1.24 ($0.02).
ImmuPharma Stock Performance
The company has a market capitalization of £4.79 million, a price-to-earnings ratio of -115.00 and a beta of 1.53. The business’s 50 day moving average is GBX 1.46 and its 200 day moving average is GBX 1.71.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
